Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals

References

• White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379(11):1060–1070.
   PubMed Web of Science ®Google Scholar
• Aydin Ö, Bavbek S, Büyüköztürk S, Çelik G, Ediger D, Erdinç M, et al. Astım Tanı ve Tedavi Rehberi 2020. Güncellemesi.
   Google Scholar
• Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L, TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116(5):970–975.
   PubMed Web of Science ®Google Scholar
• Bavbek S, Yilmaz I, Celik G, Aydin O, Erkekol FO, Orman A, Kurt E, Ediger D, Dursun B, Abadoğlu O, et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey. Allergol Immunopathol (Madr). 2012;40(4):225–230.
   PubMed Web of Science ®Google Scholar
• Comert S, Celebioglu E, Yucel T, Erdogan T, Karakaya G, Onerci M, Kalyoncu AF. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy. 2013;68(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• Kaya SÇ, Damadoğlu E, Karakaya G, Kalyoncu AF. Regular treatment with aspirin 300 mg/day after desensitization in patients with N-ERD: 12-year results. Turk Thoracic J. 2021;22(5):376–380.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Ucar S, Gumuslu S, Strauss LG. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1beta and sCD200 in cases of Samter’s syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol. 2013;35(4):524–527.
   PubMed Web of Science ®Google Scholar
• Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118(4):801–804.
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Chu DK, Stevens WW, White AA. Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease-how to choose? J Allergy Clin Immunol Pract. 2022.
   Web of Science ®Google Scholar
• Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45–53.
   PubMedGoogle Scholar
• Olivier F, George M, Leuba D, Monnier P, Friedrich JP. Long-term outcomes following functional endoscopic sinus surgery in Samter’s triad. J Laryngol Otol. 2015;129(6):548–552.
   PubMed Web of Science ®Google Scholar
• San Nicolo M, Habermann N, Havel M. AERD associated nasal polyposis: efficacy of postoperative antileukotriene therapy in comparison with aspirin desensitization. A retrospective study. Int Arch Allergy Immunol. 2020;181(10):790–798.
   PubMed Web of Science ®Google Scholar
• Scadding GK, Scadding GW. Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP). J Allergy Clin Immunol. 2021.
   Google Scholar
• Spies JW, Valera FC, Cordeiro DL, de Mendonça TN, Leite MG, Tamashiro E, Arruda LK, Anselmo-Lima WT. The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD). Braz J Otorhinolaryngol. 2016;82(3):263–268.
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Agache I, Bavbek S, Bakirtas A, Blanca M, Bochenek G, Bonini M, Heffler E, Klimek L, Laidlaw TM, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28–39.
   PubMed Web of Science ®Google Scholar
• Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17–35.
   Google Scholar
• Waldram JD, White AA. A survey of aspirin desensitization practices among allergists and fellows in training in the United States. J Allergy Clin Immunol Pract. 2016;4(6):1253–1255.
   PubMed Web of Science ®Google Scholar
• Klimek L, Dollner R, Pfaar O, Mullol J. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)? Curr Allergy Asthma Rep. 2014;14(6):441.
   PubMed Web of Science ®Google Scholar
• Stevens WW, Jerschow E, Baptist AP, Borish L, Bosso JV, Buchheit KM, Cahill KN, Campo P, Cho SH, Keswani A, et al. The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: a work group report from the rhinitis, rhinosinusitis and ocular allergy committee of the American academy of allergy. J Allergy Clin Immunol. 2021;147(3):827–844.
   PubMed Web of Science ®Google Scholar
• Klimek L, Olze H, Forster-Ruhrmann U, Beule AG, Chaker AM, Hagemann J, Huppertz T, Hoffmann TK, Dazert S, Deitmer T, et al. Positionspapier: Empfehlungen zur Anwendung von Mepolizumab bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem – Empfehlungen des Ärzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC). Laryngorhinootologie. 2022;101(4):284–294.
   Google Scholar
• Bousquet J, Anto JM, Bachert C, Haahtela T, Zuberbier T, Czarlewski W, Bedbrook A, Bosnic-Anticevich S, Walter Canonica G, Cardona V, et al. ARIA digital anamorphosis: digital transformation of health and care in airway diseases from research to practice. Allergy. 2021;76(1):168–190.
   PubMed Web of Science ®Google Scholar
• Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, Lababidi H, Ledanois O, Mahoub B, Perng DW, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–2021.
   PubMedGoogle Scholar
• Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–681.e1.
   PubMed Web of Science ®Google Scholar
• Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Cofactors and comorbidities in patients with aspirin/NSAID hypersensitivity. Allergol Immunopathol (Madr). 2017;45(6):573–578.
   PubMed Web of Science ®Google Scholar
• Erdogan T, Karakaya G, Kalyoncu AF. Comorbid diseases in aspirin-exacerbated respiratory disease, and asthma. Allergol Immunopathol (Madr). 2015;43(5):442–448.
   PubMed Web of Science ®Google Scholar
• Walgama ES, Hwang PH. Aspirin-exacerbated respiratory disease. Otolaryngol Clin North Am. 2017;50(1):83–94.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Mitsui C, Hayashi H, Ono E, Kajiwara K, Mita H, Watai K, Kamide Y, Fukutomi Y, Sekiya K, et al. Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD. Allergol Int. 2019;68(3):289–295.
   PubMed Web of Science ®Google Scholar
• Stevens WW, Ocampo CJ, Berdnikovs S, Sakashita M, Mahdavinia M, Suh L, Takabayashi T, Norton JE, Hulse KE, Conley DB, et al. Cytokines in chronic rhinosinusitis. Role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care Med. 2015;192(6):682–694.
   PubMed Web of Science ®Google Scholar
• Forster-Ruhrmann U, Zappe SM, Szczepek AJ, Olze H, Rabe U. Long-term clinical effects of aspirin-desensitization therapy among patients with poorly controlled asthma and non-steroidal anti-inflammatory drug hypersensitivity: an exploratory study. Rev Port Pneumol. 2006;2015.
   Google Scholar
• Özdemir E, Damadoğlu E, Karakaya G, Kalyoncu AF. A new classification option for NSAID hypersensitivity: kalyoncu classification. Allergol Immunopathol (Madr). 2022;50(6):122–127.
   PubMed Web of Science ®Google Scholar
• Karakaya G, Celebioglu E, Kalyoncu AF. Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma. Respir Med. 2013;107(7):967–974.
   PubMed Web of Science ®Google Scholar
• Scangas GA, Remenschneider AK, Su BM, Shrime MG, Metson R. The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2017;7(11):1035–1044.
   PubMed Web of Science ®Google Scholar
• Adelman J, McLean C, Shaigany K, Krouse JH. The role of surgery in management of Samter’s triad: a systematic review. Otolaryngol Head Neck Surg. 2016;155(2):220–237.
   PubMed Web of Science ®Google Scholar
• Gitomer SA, Fountain CR, Kingdom TT, Getz AE, Sillau SH, Katial RK, Ramakrishnan VR. Clinical examination of tissue eosinophilia in patients with chronic rhinosinusitis and nasal polyposis. Otolaryngol Head Neck Surg. 2016;155(1):173–178.
   PubMed Web of Science ®Google Scholar
• Van Hulst G, Jorssen J, Jacobs N, Henket M, Louis R, Schleich F, Bureau F, Desmet CJ. Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma. Eur Respir J. 2022;59(3):2100935.
   PubMed Web of Science ®Google Scholar
• Bajpai S, Marino MJ, Rank MA, Donaldson AM, O'Brien EK, Lal D. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: a real-world study. Int Forum Allergy Rhinol. 2021;11(8):1152–1161.
   PubMed Web of Science ®Google Scholar
• Mullur J, Steger CM, Gakpo D, Bensko JC, Maurer R, Laidlaw TM, Buchheit KM. Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience. Ann Allergy Asthma Immunol. 2022;128(5):575–582.
   PubMed Web of Science ®Google Scholar
• Wu D, Li L, Zhang M, Wang J, Wei Y. Two inflammatory phenotypes of nasal polyps and comorbid asthma. Ann Allergy Asthma Immunol. 2017;118(3):318–325.
   PubMed Web of Science ®Google Scholar
• Gelardi M, Iannuzzi L, Tafuri S, Passalacqua G, Quaranta N. Allergic and non-allergic rhinitis: relationship with nasal polyposis, asthma and family history. Acta Otorhinolaryngol Ital. 2014;34(1):36–41.
   PubMed Web of Science ®Google Scholar
• Kim SH, Choi H, Yoon MG, Ye YM, Park HS. Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype. Ann Allergy Asthma Immunol. 2015;114(3):208–213.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042.
   PubMed Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, Valero A, Gemzoe K, Maxwell A, Joksaite S, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151.
   PubMed Web of Science ®Google Scholar
• Forster-Ruhrmann U, Stergioudi D, Pierchalla G, Fluhr JW, Bergmann KC, Olze H. Omalizumab in patients with NSAIDs-exacerbated respiratory disease. Rhinology. 2020;58(3):226–232.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, Munoz X, Devouassoux G, Bergna M, Galkin D, Azmi J, Mouneimne D, Price RG, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726.
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Quarato CMI, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:1753466620929231.
   Web of Science ®Google Scholar
• Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, Price RG, Galkin DV, Azmi J, Mouneimne D, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021;22(1):144.
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Resta E, Povero M, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, et al. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Sci Rep. 2021;11(1):5453.
   PubMed Web of Science ®Google Scholar